Literature DB >> 7539173

Epidemiology and natural history of benign prostatic hyperplasia.

H A Guess1.   

Abstract

Clinical manifestations of BPH include the symptoms, signs, and sequelae of urinary obstruction caused by the abnormal growth of non-malignant nodules that arise in a small region around the proximal segment of the prostatic urethra. Although the pathologic diagnostic criteria are relatively specific, clinical diagnostic criteria are much less specific, and no single BPH case definition has gained wide acceptance for use in epidemiologic studies.

Entities:  

Mesh:

Year:  1995        PMID: 7539173

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  8 in total

1.  [PDE5 inhibitors in treatment of benign prostatic syndrome].

Authors:  P Sandner; H Tinel; B Stelte-Ludwig; J Huetter; D Neuser; E Bischoff; E Ulbrich
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 2.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 3.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

4.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

5.  A detailed safety assessment of a saw palmetto extract.

Authors:  Andrew L Avins; Stephen Bent; Suzanne Staccone; Evelyn Badua; Amy Padula; Harley Goldberg; John Neuhaus; Esther Hudes; Katusto Shinohara; Christopher Kane
Journal:  Complement Ther Med       Date:  2008-02-20       Impact factor: 2.446

Review 6.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

7.  Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.

Authors:  Andrej Jedinak; Adam Curatolo; David Zurakowski; Simon Dillon; Manoj K Bhasin; Towia A Libermann; Roopali Roy; Monisha Sachdev; Kevin R Loughlin; Marsha A Moses
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

8.  Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia.

Authors:  Mohammad Abdul Jalil Ansari; Dilruba Begum; Fakhrul Islam
Journal:  Ann Saudi Med       Date:  2008 May-Jun       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.